Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid group at the N-terminus that improves stability and extends half-life compared to native GHRH. It is the only FDA-approved GHRH analogue, which makes it among the most rigorously characterised research peptides in the GHRH class. The Certificate of Analysis on this page documents in-house HPLC purity of tesamorelin at 98.10% in the production batch.
In-House Testing
BodyPharm laboratory
- Report
- #260228
- Batch
- TS327745
- Purity (HPLC)
- 98.10%
- Concentration
- 11.6 mg/ml
Testing Methodology
In-House HPLC Verification
BodyPharm in-house report #260228 documents Reverse-Phase HPLC analysis of batch TS327745 at 98.10% purity, with concentration of 11.6 mg/ml in the pen formulation. Tesamorelin is a 44-residue peptide with an N-terminal lipid modification that produces a characteristically late retention time on RP-HPLC. The lipid modification also makes tesamorelin more lipophilic than unmodified GHRH 1-44, requiring slightly different mobile phase optimisation than for the parent sequence.
GHRH Analogue Stability and Refrigeration
Native GHRH is highly susceptible to dipeptidyl peptidase IV (DPP-IV) cleavage at the second residue, producing rapid degradation in research models. The trans-3-hexenoic acid modification at the N-terminus of tesamorelin blocks this cleavage and extends the peptide half-life sufficient for research-grade application. Solution stability requires consistent refrigeration at 2-8C; the pen formulation maintains stability through the documented shelf life. The HPLC test is performed shortly after fill and reflects the integrity of the lipid-modified peptide at dispatch.
FDA-Approved Comparator Reference
Tesamorelin is approved under the trade name Egrifta for clinical use in HIV-associated lipodystrophy. This regulatory status means the synthesis route, impurity profile, and structure-activity relationship of tesamorelin are well-characterised in the published literature. Research-grade tesamorelin from BodyPharm is supplied for laboratory study only and is not the FDA-approved formulation. The HPLC retention time on the certificate is matched against a tesamorelin reference standard, with mass-based identity confirmation available on representative batches for institutional procurement.
What This Result Means for Researchers
Tesamorelin research applications span metabolic biology, body composition models, and cognitive aging research. Multiple randomised controlled trials in clinical populations have documented changes in visceral adipose tissue (VAT) and lean mass metrics in human subjects. Research interest also extends to cognitive aging, with studies examining tesamorelin effects on memory and executive function, and to non-alcoholic fatty liver disease (NAFLD) models. Mechanistically, tesamorelin stimulates pulsatile growth hormone release from pituitary somatotrophs via the GHRH receptor, preserving the natural pulsatile release pattern more faithfully than direct growth hormone administration. Downstream IGF-1 elevation is the primary mediator of many documented effects, and research-grade material is supplied for laboratory protocols examining the GH-IGF-1 axis in controlled experimental conditions.
Frequently Asked Questions
Related Products
Tesamorelin 32 Pen
Tesamorelin 32mg pre-filled research pen, GHRH analogue with HPLC-verified purity at 98.10%.